高级检索
当前位置: 首页 > 详情页

A protein fragment derived from DNA-topoisomerase I as a novel tumour-associated antigen for the detection of early stage carcinoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Chengdu Cancer Bioengineering Research Institute, 37 Twelve Bridge Road, Chengdu 610075, Sichuan, PR China [2]Chengdu Geimmica Scientific Ltd, Chengdu, Sichuan, PR China [3]Department of Oncology, Sichuan Academy of Medical Sciences,Chengdu, Sichuan, PR China [4]Core Laboratory, Sichuan Academy of Medical Sciences, Chengdu, Sichuan, PR China [5]Laboratory of Stem Cells and Regeneration Medicine, The Affiliated Hospital of Weifang Medical University, Weifang, Shandong,PR China
出处:
ISSN:

关键词: tumour-associated antigen autoantibodies DNA-topoisomerase I early diagnosis of carcinoma TOPO48 anti-TOPO48 autoantibodies

摘要:
Background: The production of autoantibodies against tumour-associated antigens (TAAs) is believed to reflect greater immunologic reactivity in cancer patients and enhanced immune surveillance for cancer cells. Over the past few decades, a number of different TAAs and their corresponding autoantibodies have been investigated. However, positive frequency of autoantibody detection in cancer patients has been relatively low. Here we describe a novel TAA that was a fragment derived from human DNA-topoiomerase I and an autoantibody against the novel TAA with relatively high positive frequency in the sera of early-stage non-small-cell lung cancer (NSCLC), gastric cancer (GC), colorectal cancer (CRC) and oesophageal squamous cell carcinoma (ESCC). Methods: Serologic enzyme-linked immunosorbent assay (ELISA) and western blot were used to discover a novel TAA with a molecular weight of 48 kDa separated by ion exchange chromatography. Autoantibody ELISA, immnohistochemistry and immunofluorescent staining, recombinant protein cloning/expression and western blot were used to identify the novel TAA. The association of the autoantibody against the novel TAA with early-stage carcinoma was explored by screening 203 stage I/II patients and 170 stage III/IV patients with NSCLC, GC, CRC or ESCC. Results: We identified the novel TAA as a fragment derived from human DNA-topoiomerase I (TOP1). We found that the novel TAA induced specific autoantibodies with a high prevalence that ranged from 58 to 72% in some of the most common types of cancer. We observed that the immune response against the novel TAA was associated with early stage ESCC, GC, CRC and NSCLC. Conclusions: The findings in this study suggest that the autoantibody against the novel TAA may be a potential biomarker for use in the early detection and diagnosis of cancer.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 2 区 医学
小类 | 2 区 肿瘤学
最新[2023]版:
大类 | 1 区 医学
小类 | 2 区 肿瘤学
JCR分区:
出版当年[2016]版:
Q1 ONCOLOGY
最新[2023]版:
Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Chengdu Cancer Bioengineering Research Institute, 37 Twelve Bridge Road, Chengdu 610075, Sichuan, PR China [2]Chengdu Geimmica Scientific Ltd, Chengdu, Sichuan, PR China [3]Department of Oncology, Sichuan Academy of Medical Sciences,Chengdu, Sichuan, PR China
通讯作者:
通讯机构: [1]Chengdu Cancer Bioengineering Research Institute, 37 Twelve Bridge Road, Chengdu 610075, Sichuan, PR China [2]Chengdu Geimmica Scientific Ltd, Chengdu, Sichuan, PR China [3]Department of Oncology, Sichuan Academy of Medical Sciences,Chengdu, Sichuan, PR China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43372 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号